"In-depth" 510(k) reviews will be completed within 90 days, CDRH's Burlington says.
This article was originally published in The Gray Sheet
Executive Summary
"IN-DEPTH REVIEW" ON ALL 510(K) SUBMISSIONS WITHIN 90 DAYS will be pursued by FDA's Center for Devices and Radiological Health for fiscal year 1996 (begun Oct. 1), CDRH Director Bruce Burlington says in a letter highlighting improvements in the center's device review program. "Our goal is to screen for completeness and perform at least one cycle of in-depth review on all submissions within a 90-day review cycle," Burlington says, at which time sponsors can expect to receive a determination of substantially equivalent, not substantially equivalent, or a request for additional data.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.